Navigation Links
Study finds potential key to immune suppression in cancer
Date:1/19/2012

TAMPA, Fla. In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) cells that play a major role in cancer-related immune suppression dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's CD8 T cells.

Their study appeared in a recent issue of Cancer Research, published by the American Association for Cancer Research.

According to the authors, it has been established that inadequate immune response in cancer is a critical element in tumor escape, and that myeloid-derived suppressor cells (MDSCs) cells that which normally keep the immune system in check and prevent it from attacking otherwise healthy tissue can suppress the anti-tumor response and play a major role in tumor associated immune abnormalities.

In addition, research has shown that MDSCs block other immune system cells (such as CD 8 "killer" T cells) from binding with proteins that identify foreign antigens on the surface of unhealthy cancer cells and, in doing so, mark them as targets.

"To better understand the biology of immune defects in cancer, our study investigated the antigen-specific nature of MDSCs and their ability to cause antigen specific CD4 T cell tolerance," said study corresponding author Dmitry Gabrilovich, M.D., Ph.D., who holds the Robert Rothman Endowed Chair in Cancer Research at Moffitt and whose research focus is on immunology. "We found that antigen specific CD4 T cells were able to dramatically enhance the immune suppressive activity of MDSC by converting them into powerful non-specific suppressors. But, to our surprise, we did not see the same response from CD8 T cells."

The researchers initially investigated several tumors modeled in mice but focused on two models of particular interest.

They reported that major histocompatability complex (MHC) class II molecules found only on a few specialized cell types played a role in this conversion to MDSC-mediated suppression when MHC class II and MDSC "cross-linked" through cell-to-cell contact. The effect, however, was dependent on the expression of MHC class II.

"This study showed for the first time that activated antigen-specific T-cells can potentiate the immune suppressive activity of MDSC by converting these cells to non-specific suppressors and, thus, limit the ability of the host to mount a potent immune response," concluded the authors.

The researchers suggested that their study might shed light on a mechanism that may act as a "negative feedback loop" aimed at controlling immune responses that become "dysregulated" in cancer.


'/>"/>
Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Excel ... Mike Finnegan to the position of Executive Vice President, Sales and Marketing. Finnegan ... technology, telehealth and medical device sales leadership. He has received industry recognition for ...
(Date:6/27/2017)... Philadelphia PA and London UK (PRWEB) , ... June 27, 2017 ... ... for applying to a clinical study is whether they can trust the sponsor to ... competitive, it is vital that sponsors and CROs establish payment strategies that encourage sites ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the cloud-based payment ... care industry’s hospitals and provider groups, has announced that it will now offer ... Health is a San Francisco health-finance startup that has launched a series of ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on ... efforts, Louisiana became the sixth state to pass legislation which ensures that children ... Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington ...
(Date:6/27/2017)... California (PRWEB) , ... June 27, 2017 , ... A ... has been projected to reach a staggering $6.81 billion by the year 2024 according ... rising at a faster rate than those made from titanium. Los Angeles area clinic ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the ... President of R&D and Head of Virology Kristin Bedard has ... the Northwest and Beyond meeting sponsored by Life Science ... from 8:30-10:30 AM PDT at the Agora Conference Center in ... Bedard will be joined by other leaders in infectious disease ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology: